Abstract
Historically, the prime goal of drug development has been the development of a blockbuster drug, i.e. a drug generating more than $1 billion of revenue for its owner (Fig. 1). Classical examples of blockbuster classes of drugs are the statins, non-steroidal anti-inflammatory drugs (NSAIDs) or proton pump inhibitors (PPIs), which can be prescribed to millions of patients for a broad variety of disease states.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Clinton HR, Obama B (2006) Making patient safely the centerpiece of medical liability reform. NEJM 354: 2205–2208
The Presidential Council of Advisors on Science and Technology (PCAST) (2008) Report on Personalized Medicine. http://www.ostp.gov/galleries/PCAST/pcast_report_v2.pdf
Müller M, Müller-Zellenberg U, Hochhaus G, Derendorf H (2001) Current concepts in clinical pharmacokinetics and their implications for clinical medicine. Wien Klin Wochenschr 113: 566–572
Waite AE (1894) The Hermetic and Alchemical Writings of Aureolus Philippus Theophrastus Bombast of Hohenheim Called Paracelsus the Great, Vol. 2. Elliott & Co., London
Ober KP (1997) The Pre-Flexnerian reports: Mark Twain’s criticism of medicine in the United States. Ann Intern Med 126: 157–163
Sheiner LB, Tozer TN (1978) Clinical pharmacokinetics: the use of plasma concentrations of drugs. In: Melmon KL, Morelli HF (eds.) Clinical pharmacology: basic principles of therapeutics. MacMillan, New York, pp. 71–109
Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH (1998) Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338(8): 499–505
Müller M (2003) Pharmacogenomics and drug response. Int J Clin Pharmacol Ther 41(6): 231–240
Motulsky AG (1957) Drug reactions, enzymes and biochemical genetics. JAMA 165: 835–836
Vesell ES, Page JG (1968) Genetic control of drug levels in man: antipyrine. Science 161(836): 72–73
Vesell ES, Page JG (1968) Genetic control of drug levels in man: phenylbutazone. Science 159(822): 1479–1480
Vesell ES (2000) Advances in pharmacogenetics and pharmacogenomics. J Clin Pharmacol 40(9): 930–938
Carsen PE, Flanagan CL, Iokes CE, Alving AS (1956) Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 124: 484–485
Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE (1999) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltrans-ferase gene locus. J Natl Cancer Inst 91(23): 2001–2089
Mancinelli L, Cronin M, Sadee W (2000) Pharmacogenomics: The Promise of Personalized Medicine. (http://www.pharmsci.Org/ScientificJournals/pharmsci/journal/4.html) AAPS Pharmsci 2(1): article 4
Dollery CT (2007) Beyond genomics. Clin Pharmacol Ther 82(4): 366–370
The Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661–678
Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Müller CR, Strom TM, Oldenburg J (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427(6974): 537–541
International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360(8): 753–764. Erratum in: N Engl J Med 2009 361(16): 1613 (Dosage error in article text)
Michiels S, Koscielny S, Hill C (2005) Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365(9458): 488–492
Trusheim MR, Berndt ER, Douglas FL (2007) Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 6(4): 287–293
Arnett DK, Claas SA, Lynch AI (2009) Has pharmacogenetics brought us closer to ‘personalized medicine’ for initial drug treatment of hypertension? Curr Opin Cardiol 24: 333–339
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag/Wien
About this chapter
Cite this chapter
Müller, M. (2010). Individualized medicine. In: Müller, M. (eds) Clinical Pharmacology: Current Topics and Case Studies. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0144-5_22
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0144-5_22
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-0143-8
Online ISBN: 978-3-7091-0144-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)